Henrik Alfthan

526 total citations
6 papers, 380 citations indexed

About

Henrik Alfthan is a scholar working on Reproductive Medicine, Genetics and Oncology. According to data from OpenAlex, Henrik Alfthan has authored 6 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Reproductive Medicine, 2 papers in Genetics and 2 papers in Oncology. Recurrent topics in Henrik Alfthan's work include Ovarian cancer diagnosis and treatment (3 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers) and Gestational Trophoblastic Disease Studies (2 papers). Henrik Alfthan is often cited by papers focused on Ovarian cancer diagnosis and treatment (3 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers) and Gestational Trophoblastic Disease Studies (2 papers). Henrik Alfthan collaborates with scholars based in Finland and Canada. Henrik Alfthan's co-authors include Ulf‐Håkan Stenman, Eleftherios P. Diamandis, S. Fracchioli, M. Van Gramberen, Andreas Scorilas, M Massobrio, Ignace Vergote, Dionyssios Katsaros, Linda Grass and Antoninus Soosaipillai and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Cancer and Pediatric Research.

In The Last Decade

Henrik Alfthan

6 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henrik Alfthan Finland	5	160	146	112	112	72	6	380
Shannon J.C. Shan United States	8	140 0.9×	74 0.5×	99 0.9×	25 0.2×	47 0.7×	9	343
Pavankumar N.G. Reddy Germany	10	82 0.5×	360 2.5×	100 0.9×	107 1.0×	38 0.5×	12	616
Maurizia Giai Italy	9	103 0.6×	281 1.9×	136 1.2×	19 0.2×	70 1.0×	13	573
Joachim Rehbock Germany	12	94 0.6×	236 1.6×	92 0.8×	93 0.8×	74 1.0×	25	531
Etsuko Miyagi Japan	9	62 0.4×	175 1.2×	52 0.5×	33 0.3×	101 1.4×	11	404
Tomáš Frgala United States	11	41 0.3×	219 1.5×	120 1.1×	26 0.2×	54 0.8×	16	386
Masashi Moriyama Japan	8	78 0.5×	118 0.8×	125 1.1×	38 0.3×	63 0.9×	15	383
Terrence J. Colgan Canada	6	54 0.3×	147 1.0×	93 0.8×	65 0.6×	28 0.4×	8	339
D. H. Rutgers Netherlands	12	21 0.1×	248 1.7×	147 1.3×	121 1.1×	91 1.3×	17	502
Yulei Shen United States	12	59 0.4×	327 2.2×	90 0.8×	11 0.1×	147 2.0×	24	519

Countries citing papers authored by Henrik Alfthan

Since Specialization

Citations

This map shows the geographic impact of Henrik Alfthan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Alfthan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Alfthan more than expected).

Fields of papers citing papers by Henrik Alfthan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Alfthan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Alfthan. The network helps show where Henrik Alfthan may publish in the future.

Co-authorship network of co-authors of Henrik Alfthan

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Alfthan. A scholar is included among the top collaborators of Henrik Alfthan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Alfthan. Henrik Alfthan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Diamandis, Eleftherios P., Andreas Scorilas, S. Fracchioli, et al.. (2003). Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. Journal of Clinical Oncology. 21(6). 1035–1043. 167 indexed citations

2.

Luo, Liu‐Ying, Dionyssios Katsaros, Andreas Scorilas, et al.. (2003). The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.. PubMed. 63(4). 807–11. 131 indexed citations

3.

Vartiainen, Juhani, et al.. (2001). Preoperative serum concentration of hCG? as a prognostic factor in ovarian cancer. International Journal of Cancer. 95(5). 313–316. 28 indexed citations

4.

Lehtovirta, Pentti, Henrik Alfthan, Juhani Vartiainen, & Ulf‐Håkan Stenman. (1999). Skin Metastases of Gynecologic Adenocarcinomas Affect Serum Levels of hCGβ but Not Those of SCC Antigen. Tumor Biology. 20(5). 251–255. 2 indexed citations

5.

Vartiainen, Juhani, Henrik Alfthan, Pentti Lehtovirta, & Ulf‐Håkan Stenman. (1998). Identification of choriocarcinoma by the hCGβ-to-hCG proportion in patients with delayed diagnosis caused by contraceptive use. Contraception. 57(4). 257–260. 10 indexed citations

6.

Alfthan, Henrik, et al.. (1994). A Clinically Useful Method for Detecting Gonadotropins in Children: Assessment of Luteinizing Hormone and Follicle-Stimulating Hormone from Urine as an Alternative to Serum by Ultrasensitive Time-Resolved Immunofluorometric Assays. Pediatric Research. 36(2). 221–226. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact